Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Mitotic Pathway Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RACGAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RACGAP1 Recombinant Protein (GAP Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic and PPI assays. |
View RACGAP1 Products |
| Gene Delivery | RACGAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and knockdown rescue. |
View RACGAP1 Products |
| Benchmark Ab | Anti-RACGAP1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and immunoprecipitation. |
View RACGAP1 Products |
| Validator | RACGAP1 siRNA Set For functional knockdown verification in phenotypic assays. |
View RACGAP1 Products |
| Related Target A | KIF23 (MKLP1) Mitotic kinesin partner forming the centralspindlin complex with RACGAP1; key target for protein-protein interaction (PPI) disruption. |
View KIF23 Products |
| Related Target B | RAC1 Primary GTPase substrate of RACGAP1; essential for validating GTPase-activating protein (GAP) activity. |
View RAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (RACGAP1-KIF23) | High-purity recombinant proteins with precise tag configurations (GST/His) for TR-FRET and AlphaLISA. |
| GTPase-activating protein (GAP) enzymatic validation | Sequence-verified active domains expressed in native-like systems to ensure correct folding. |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay standardization. |
| False Positives | Validated siRNA sets included for target-specific knockdown controls. |
Live RACGAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RACGAP1 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic therapies to targeted mitotic machinery inhibitors and RNA-based therapeutics. As first-generation cell-cycle checkpoint therapies reach the clinic, the next wave of R&D is targeting the centralspindlin complex to selectively induce mitotic catastrophe in rapidly dividing cancer cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Institutions, Biotech Startups | Colorectal Cancer, Hepatocellular Carcinoma | Protein-Protein Interaction assays (Requires high-purity, sequence-verified RACGAP1 and KIF23 proteins) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Solid Tumors, Triple-Negative Breast Cancer | Target knockdown validation (Requires validated siRNA sets and Lentivirus for rescue assays) |
| Cancer Peptide Vaccines | Oncology Research Consortia | Pancreatic Cancer, Esophageal Cancer | Epitope mapping and stability profiling (Requires high-purity recombinant antigen fragments) |